Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Ozoralizumab

(Synonyms: TS-152, ATN-103) Copy Product Info
🥰Excellent

Synonyms: TS-152, ATN-103

Catalog No. T77126 Copy Product Info
🥰Excellent
Ozoralizumab (ATN-103) is a humanized anti-TNFα antibody and a novel TNFα inhibitor.Ozoralizumab binds human serum albumin and can be used to study rheumatoid arthritis.

Ozoralizumab

Cas No. 1167985-17-2
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$328In StockIn Stock
5 mg$859In StockIn Stock
10 mg$1,270In StockIn Stock
25 mg$1,890-In Stock
50 mg$2,550-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:95.6% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Ozoralizumab (ATN-103) is a humanized anti-TNFα antibody and a novel TNFα inhibitor.Ozoralizumab binds human serum albumin and can be used to study rheumatoid arthritis.
In vitro
METHODS: Ozoralizumab (ATN-103) (0.1-1000pM) was used to treat L929 cells and its high TNFα neutralizing potency was determined.
RESULTS: Ozoralizumab (ATN-103) has high TNFα neutralizing potency, with very similar binding and dissociation properties, and KD values ​​for human TNFα and monkey TNFα are 20.2 pM and 16.1 pM, respectively. [1]
In vivo
METHODS: Tg197 mice were injected subcutaneously with 1 mg/kg dose of Ozoralizumab (ATN-103) twice weekly to evaluate the formation of ADA against each anti-TNFα antibody and the effect of long-term administration of these anti-TNFα antibodies on TNFα-mediated TNFα in Tg197 mice. Efficacy of polyarthritis.
RESULTS: Ozoralizumab (ATN-103) significantly and comparably reduced arthritis scores. [1]
SynonymsTS-152, ATN-103
Reactivity
Human
Verified Activity
Immobilized Human TNFa Protein at 2 μg/mL can bind Ozoralizumab (VHH). The EC50 is 0.004992 μg/mL.
Ozoralizumab
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetTNFSF2/TNFa
Chemical Properties
Molecular Weight38.44 kDa
Cas No.1167985-17-2
Antibody Information
IsotypeVHH1-VHH2-VHH1
Storage & Solubility Information
StorageStore at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: Ozoralizumab in vivo | Ozoralizumab in vitro | Ozoralizumab molecular weight